- Home
- GRAL vs KROS Comparison
GRAL vs KROS Comparison
Compare GRAL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- KROS
- Stock Information
- Founded
- GRAL 2016
- KROS 2015
- Country
- GRAL United States
- KROS United States
- Employees
- GRAL N/A
- KROS N/A
- Industry
- GRAL
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- KROS Health Care
- Exchange
- GRAL NYSE
- KROS Nasdaq
- Market Cap
- GRAL 1.6B
- KROS 558.9M
- IPO Year
- GRAL N/A
- KROS 2020
- Fundamental
- Price
- GRAL $38.72
- KROS $14.28
- Analyst Decision
- GRAL Buy
- KROS Buy
- Analyst Count
- GRAL 3
- KROS 13
- Target Price
- GRAL $31.50
- KROS $20.63
- AVG Volume (30 Days)
- GRAL 1.3M
- KROS 467.7K
- Earning Date
- GRAL 08-12-2025
- KROS 08-06-2025
- Dividend Yield
- GRAL N/A
- KROS N/A
- EPS Growth
- GRAL N/A
- KROS N/A
- EPS
- GRAL N/A
- KROS 0.11
- Revenue
- GRAL $130,711,000.00
- KROS $214,713,000.00
- Revenue This Year
- GRAL $19.52
- KROS $5,006.76
- Revenue Next Year
- GRAL $20.37
- KROS N/A
- P/E Ratio
- GRAL N/A
- KROS $131.15
- Revenue Growth
- GRAL 30.47
- KROS 91657.70
- 52 Week Low
- GRAL $12.33
- KROS $9.12
- 52 Week High
- GRAL $63.99
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- KROS 63.37
- Support Level
- GRAL N/A
- KROS $13.26
- Resistance Level
- GRAL N/A
- KROS $14.83
- Average True Range (ATR)
- GRAL 0.00
- KROS 0.40
- MACD
- GRAL 0.00
- KROS 0.13
- Stochastic Oscillator
- GRAL 0.00
- KROS 79.87
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.